On August !, 2013, BioCryst Pharmaceuticals Inc. (BCRX) disclosed in a regulatory filing that on July 31, the company was notified by the United States Food and Drug Administration (FDA) that the agency lifted the clinical hold placed on its hereditary angioedema (HAE) drug BCX 4161. The FDA notified BioCryst that the complete response letter (CRL) submitted by BioCryst in response to the hold satisfactorily addressed its concerns. BioCryst can now conduct clinical trials in the United States to further the development of BCX 4161. BioCryst stock was up over 20% after the news.
On July 30-31, BioCryst announced to sell up to 4 million shares of stock at $4.40 per share...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: